BioCentury
ARTICLE | Clinical News

Evofosfamide: Development discontinued

December 14, 2015 8:00 AM UTC

Threshold and partner Merck discontinued development of evofosfamide to treat STS after the open-label, international Phase III TH-CR-406/SARC021 trial in 640 patients with locally advanced unresectab...